In February 2020, Recipharm acquired Consort Medical plc, which included Bespak. The move was designed to strengthen Recipharm’s position as a leading inhalation company and one of the largest CDMOs in the world.
Combining pharma expertise with device capabilities
The combination of Recipharm and Bespak – a leading player in the manufacture of innovative drug delivery devices – is highly complementary as both companies provide different products and services within the same value chain for a number of customers. The acquisition combines Recipharm’s deep pharma development and manufacturing expertise with Bespak’s innovative device capabilities. This ultimately allows us to create an entirely new offering in device development and manufacturing, with many exciting potential synergies with Recipharm’s existing business.
With this in mind, we are excited to announce that we have launched Bespak by Recipharm. The brand will become part of Recipharm Inhalation Solutions™, as well as continuing to provide unrivalled medical device expertise to the industry, alongside Recipharm wider portfolio.
Building leadership in inhalation
As a result of the integration Recipharm is now a leading end-to-end global inhalation technology CDMO with a strong IP portfolio and blue-chip customer base. The acquisition also adds scale and additional capabilities to Recipharm’s current inhalation portfolio, as well as enabling the company to diversify into non-respiratory inhalation products.
The acquisition has significantly enhanced our customer value proposition as a leading provider of valves and dose-counters for MDIs, DPI devices and the innovative nasal spray Unidose® Xtra. In addition, the VapourSoft® Technology Platform that enables the injection of highly viscous liquids using a gentle release of a pressurised vapour has also been added to the Recipharm portfolio. This platform, along with a robust patent portfolio, is of significant benefit for many biological compounds, which tend to be viscous in nature and offers an alternative to traditional spring-loaded devices.
The platform is validated through development contracts with three major biopharma companies to date. Other new device development opportunities include exposure to the ophthalmology market and the high growth of the care diagnostics market through interests in Binx Health and Oxular. This is expected to broaden our innovative technology offering.
About Bespak by Recipharm: Bespak by Recipharm delivers market leading design, development and manufacture of drug delivery devices to the global pharmaceutical market. This includes inhaler, nasal technologies and auto-injectors as well as development and manufacturing services. Recipharm is at the leading edge of drug delivery device innovation. Driven by customer and patient demand, our innovations have the potential to create new treatments and opportunities across the globe as well as accelerating routes to market.
Bespak by Recipharm’s inhaler and nasal technologies expertise forms part of Recipharm Inhalation Solutions™, an end-to-end solution spanning early phase development to commercial manufacture of both inhalation drug product and device.
Join Miles Kottman & Neil Cropper on a webinar entitled Moving from device concept to commercial – industrialising with technology by Bespak by Recipharm on 9th November at 3PM London/10AM New York
To learn more about Bespak by Recipharm, please visit their Insights page.